Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) rose 8.6% on Thursday . The stock traded as high as $26.77 and last traded at $25.00. Approximately 24,396 shares changed hands during trading, a decline of 62% from the average daily volume of 64,964 shares. The stock had previously closed at $23.03.
Analyst Ratings Changes
Separately, Weiss Ratings began coverage on shares of Anbio Biotechnology in a research note on Monday, January 26th. They set a “sell (d+)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Anbio Biotechnology presently has an average rating of “Sell”.
Check Out Our Latest Stock Report on NNNN
Anbio Biotechnology Stock Up 10.7%
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Featured Articles
- Five stocks we like better than Anbio Biotechnology
- The day the gold market broke
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Your Bank Account Is No Longer Safe
- What a Former CIA Agent Knows About the Coming Collapse
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
